Celldex Therapeutics
CLDX
$37.00
Share price
1.93%
Change (1 day)
18.02%
Change (1 year)
Categories
Operating Margin for Celldex Therapeutics (CLDX)
Operating Margin as of April 2024 (TTM): -1,520.92%
According to Celldex Therapeutics's latest financial reports and stock price the company's current Operating Margin is -1,520.92%. At the end of 2021 the company had an Operating Margin of -1,520.92%.
Operating Margin history for Celldex Therapeutics from 2001 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -1,520.92% | 85.11% |
| 2020 | -821.61% | -42.3% |
| 2019 | -1,423.96% | -10.62% |
| 2018 | -1,593.09% | 73.05% |
| 2017 | -920.61% | -51.39% |
| 2016 | -1,894.05% | -18.4% |
| 2015 | -2,321.11% | -29.51% |
| 2014 | -3,292.81% | 65.99% |
| 2013 | -1,983.70% | 275.85% |
| 2012 | -527.79% | 9.15% |
| 2011 | -483.53% | 8832.41% |
| 2010 | -5.41% | -97.78% |
| 2009 | -244.10% | -46.47% |
| 2008 | -456.04% | 6.95% |
| 2007 | -426.40% | 3.81% |
| 2006 | -410.74% | -32.76% |
| 2005 | -610.85% | 208.46% |
| 2004 | -198.03% | -21.81% |
| 2003 | -253.28% | 17.67% |
| 2002 | -215.25% | -70.68% |
| 2001 | -734.07% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 34.61% | -102.28% | 🇺🇸 USA |
 Amgen AMGN | 34.59% | -102.27% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 22.54% | -101.48% | 🇬🇧 UK |
 Titan Pharmaceuticals
TTNP | -2,570.78% | 69.03% | 🇺🇸 USA |
 Seagen
SGEN | -30.69% | -97.98% | 🇺🇸 USA |
 Agenus
AGEN | -9.71% | -99.36% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 17.53% | -101.15% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.